95.23 - 97.14
55.47 - 103.81
1.63M / 1.81M (Avg.)
55.57 | 1.74
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.28%
Negative revenue growth while NEM stands at 20.62%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-17.67%
Negative gross profit growth while NEM is at 31.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
-6.08%
Negative EBIT growth while NEM is at 46.48%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-6.08%
Negative operating income growth while NEM is at 46.48%. Joel Greenblatt would press for urgent turnaround measures.
30.00%
Net income growth at 50-75% of NEM's 40.58%. Martin Whitman would question fundamental disadvantages in expenses or demand.
75.00%
EPS growth above 1.5x NEM's 39.74%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
75.00%
Diluted EPS growth above 1.5x NEM's 38.96%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.40%
Share count expansion well above NEM's 0.20%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.45%
Diluted share count expanding well above NEM's 0.60%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
5.22%
OCF growth under 50% of NEM's 13.41%. Michael Burry might suspect questionable revenue recognition or rising costs.
5.22%
FCF growth under 50% of NEM's 17.51%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
210.94%
10Y revenue/share CAGR 1.25-1.5x NEM's 179.65%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
149.23%
5Y revenue/share CAGR 1.25-1.5x NEM's 101.84%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
51.45%
3Y revenue/share CAGR 1.25-1.5x NEM's 44.66%. Bruce Berkowitz might see better product or regional expansions than the competitor.
1261.50%
10Y OCF/share CAGR above 1.5x NEM's 246.85%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
330.54%
5Y OCF/share CAGR above 1.5x NEM's 76.79%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
67.97%
3Y OCF/share CAGR above 1.5x NEM's 40.82%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
No Data
No Data available this quarter, please select a different quarter.
426.93%
5Y net income/share CAGR 1.25-1.5x NEM's 285.56%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
133.14%
3Y net income/share CAGR above 1.5x NEM's 24.02%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1497.53%
10Y equity/share CAGR above 1.5x NEM's 227.30%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
453.49%
5Y equity/share CAGR above 1.5x NEM's 32.76%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
68.14%
3Y equity/share CAGR 1.25-1.5x NEM's 47.19%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.44%
Firm’s AR is declining while NEM shows 25.43%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
-0.67%
Negative asset growth while NEM invests at 7.06%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
6.55%
Similar to NEM's 6.89%. Walter Schloss finds parallel capital usage or profit distribution strategies.
-5.88%
We’re deleveraging while NEM stands at 22.95%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-19.14%
We cut SG&A while NEM invests at 12.50%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.